{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:59:59Z","timestamp":1794657599115,"version":"4.9.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T00:00:00Z","timestamp":1529280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40360-018-0224-3","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T13:06:51Z","timestamp":1529327211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Stent thrombosis associated with drug eluting stents on addition of cilostazol to the standard dual antiplatelet therapy following percutaneous coronary intervention: a systematic review and meta-analysis of published randomized controlled trials"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3269-7530","authenticated-orcid":false,"given":"Feng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,18]]},"reference":[{"issue":"1","key":"224_CR1","doi-asserted-by":"publisher","first-page":"e0169807","DOI":"10.1371\/journal.pone.0169807","volume":"12","author":"PK Bundhun","year":"2017","unstructured":"Bundhun PK, Soogund MZ, Huang WQ. Same day discharge versus overnight stay in the hospital following percutaneous coronary intervention in patients with stable coronary artery disease: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2017;12(1):e0169807.","journal-title":"PLoS One"},{"issue":"1","key":"224_CR2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12872-017-0515-4","volume":"17","author":"PK Bundhun","year":"2017","unstructured":"Bundhun PK, Yanamala CM, Huang WQ. Comparing stent thrombosis associated with Zotarolimus eluting stents versus Everolimus eluting stents at 1 year follow up: a systematic review and meta-analysis of 6 randomized controlled trials. BMC Cardiovasc Disord. 2017;17(1):84.","journal-title":"BMC Cardiovasc Disord"},{"key":"224_CR3","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu298","volume":"35","author":"S Windecker","year":"2014","unstructured":"Task Force members, Windecker S, Kolh P, Alfonso F, et al. 2014 ESC\/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541\u2013619.","journal-title":"Eur Heart J"},{"key":"224_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12872-015-0114-1","volume":"15","author":"PK Bundhun","year":"2015","unstructured":"Bundhun PK, Qin T, Chen MH. Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2015;15:118.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"224_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2014-000068","volume":"1","author":"S Bangalore","year":"2014","unstructured":"Bangalore S, Singh A, Toklu B, DiNicolantonio JJ, Croce K, Feit F, Bhatt DL. Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. Open Heart. 2014;1(1):e000068.","journal-title":"Open Heart."},{"issue":"9","key":"224_CR6","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.3760\/cma.j.issn.0366-6999.20122839","volume":"126","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Tang HQ, Li J, Fu ZX. Efficacy and safety of triple-antiplatelet therapy after percutaneous coronary intervention: a meta-analysis. Chin Med J. 2013;126(9):1750\u20134.","journal-title":"Chin Med J"},{"key":"224_CR7","doi-asserted-by":"crossref","unstructured":"Cutlip DE, Windecker S, Mehran R, et al; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115(17):2344\u20132351.","DOI":"10.1161\/CIRCULATIONAHA.106.685313"},{"key":"224_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"224_CR9","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcareinterventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ"},{"issue":"1","key":"224_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1253\/circj.72.35","volume":"72","author":"Y Ahn","year":"2008","unstructured":"Ahn Y, Jeong MH, Jeong JW, Kim KH, Ahn TH, Kang WC, Park CG, Kim JH, Chae IH, Nam CW, Hur SH, Bae JH, Kim KY, Oh SK. Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabeticpatients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial. Circ J. 2008;72(1):35\u20139.","journal-title":"Circ J"},{"issue":"7","key":"224_CR11","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1177\/0003319712474113","volume":"64","author":"W Gao","year":"2013","unstructured":"Gao W, Zhang Q, Ge H, Guo Y, Zhou Z. Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation. Angiology. 2013;64(7):554\u20138.","journal-title":"Angiology"},{"issue":"4","key":"224_CR12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ahj.2009.01.006","volume":"157","author":"Y Han","year":"2009","unstructured":"Han Y, Li Y, Wang S, Jing Q, Wang Z, Wang D, Shu Q, Tang X. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneouscoronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J. 2009;157(4):733\u20139.","journal-title":"Am Heart J"},{"issue":"10","key":"224_CR13","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/j.jacc.2005.07.048","volume":"46","author":"SW Lee","year":"2005","unstructured":"Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM, Han KH, Lee CW, Kang DH, Song JK, Kim JJ, Park SJ. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol. 2005;46(10):1833\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"224_CR14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.amjcard.2009.08.667","volume":"105","author":"SW Lee","year":"2010","unstructured":"Lee SW, Chun KJ, Park SW, Kim HS, Kim YH, Yun SC, Kim WJ, Lee JY, Park DW, Lee CW, Hong MK, Rhee KS, Chae JK, Ko JK, Park JH, Lee JH, Choi SW, Jeong JO, Seong IW, Jon S, Cho YH, Lee NH, Kim JH, Park SJ. Comparison of triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and \u2013LONG trials). Am J Cardiol. 2010;105(2):168\u201373.","journal-title":"Am J Cardiol"},{"key":"224_CR15","doi-asserted-by":"crossref","unstructured":"Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Kang SJ, Park SJ, Lee JH, Choi SW, Seong IW, Lee NH, Cho YH, Shin WY, Lee SJ, Lee SW, Hyon MS, Bang DW, Choi YJ, Kim HS, Lee BK, Lee K, Park HK, Park CB, Lee SG, Kim MK, Park KH, Park WJ; DECLARE-LONG II Study Investigators. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dualantiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronarylesions: results from the DECLARE-LONG II (drug-eluting stenting followed by Cilostazol treatment reduces late restenosis in patients with long coronary lesions) trial. J Am Coll Cardiol 2011;57(11):1264\u20131270.","DOI":"10.1016\/j.jacc.2010.10.035"},{"issue":"3","key":"224_CR16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jacc.2010.08.631","volume":"57","author":"JW Suh","year":"2011","unstructured":"Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, Cho YS, Youn TJ, Chae IH, Choi DJ, Rha SW, Bae JH, Kwon TG, Bae JW, Cho MC, Kim HS. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascularcomplications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol. 2011;57(3):280\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"224_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ahj.2013.08.028","volume":"167","author":"YJ Youn","year":"2014","unstructured":"Youn YJ, Lee JW, Ahn SG, Lee SH, Choi H, Yu CW, Hong YJ, Kwon HM, Hong MK, Jang Y, Yoon J. Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy afterbiolimus-eluting stent implantation for long or multivessel coronary artery disease. Am Heart J. 2014;167(2):241\u2013248.e1.","journal-title":"Am Heart J"},{"issue":"1","key":"224_CR18","first-page":"23","volume":"12","author":"HC Zhu","year":"2015","unstructured":"Zhu HC, Li Y, Guan SY, Li J, Wang XZ, Jing QM, Wang ZL, Han YL. Efficacy and safety of individually tailored antiplatelet therapy in patients with acute coronarysyndrome after coronary stenting: a single center, randomized, feasibility study. J Geriatr Cardiol. 2015;12(1):23\u20139.","journal-title":"J Geriatr Cardiol"},{"issue":"9","key":"224_CR19","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.jcin.2013.04.022","volume":"6","author":"KW Park","year":"2013","unstructured":"Park KW, Kang SH, Park JJ, Yang HM, Kang HJ, Koo BK, Park BE, Cha KS, Rhew JY, Jeon HK, Shin ES, Oh JH, Jeong MH, Kim S, Hwang KK, Yoon JH, Lee SY, Park TH, Moon KW, Kwon HM, Chae IH, Kim HS. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (harmonizing optimal strategy for treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen). JACC Cardiovasc Interv. 2013;6(9):932\u201342.","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"224_CR20","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3892\/etm.2013.1238","volume":"6","author":"H Zhou","year":"2013","unstructured":"Zhou H, Feng XL, Zhang HY, Xu FF, Zhu J. Triple versus dual antiplatelet therapy for coronary heart disease patients undergoing percutaneous coronary intervention: a meta-analysis. Exp Ther Med. 2013;6(4):1034\u201340.","journal-title":"Exp Ther Med"},{"issue":"1","key":"224_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1185\/03007995.2013.850067","volume":"30","author":"Y Chen","year":"2014","unstructured":"Chen Y, Zhang Y, Tang Y, Huang X, Xie Y. Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. Curr Med Res Opin. 2014;30(1):37\u201349.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"224_CR22","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/1074248412468944","volume":"18","author":"XL Ding","year":"2013","unstructured":"Ding XL, Xie C, Jiang B, Gao J, Zhang LL, Zhang H, Zhang JJ, Miao LY. Efficacy and safety of adjunctive cilostazol to dual antiplatelet therapy after stent implantation: an updated meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2013;18(3):222\u20138.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"1","key":"224_CR23","doi-asserted-by":"publisher","first-page":"e000068","DOI":"10.1136\/openhrt-2014-000068","volume":"1","author":"S Bangalore","year":"2014","unstructured":"Bangalore S, Singh A, Toklu B, DiNicolantonio JJ, Croce K, Feit F, Bhatt DL. Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoingpercutaneous coronary intervention: insights from a meta-analysis of randomised trials. Open Heart. 2014;1(1):e000068.","journal-title":"Open Heart"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-018-0224-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-018-0224-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-018-0224-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T15:00:21Z","timestamp":1720364421000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-018-0224-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,18]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["224"],"URL":"https:\/\/doi.org\/10.1186\/s40360-018-0224-3","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,18]]},"assertion":[{"value":"17 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not applicable for this systematic review and meta-analysis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declare that he has no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"31"}}